Adagio Medical's VT Ablation System Shows Promise Amidst Safety Concerns

TL;DR

**ADGM's promising VT ablation tech is a high-risk, high-reward play, but the reported patient deaths in trials are a major red flag for FDA approval and future adoption.**

AI Summary

Adagio Medical Holdings, Inc. (ADGM) reported a market value of common stock held by non-affiliates at $7.0 million as of June 30, 2025, with 22,210,459 shares outstanding as of March 23, 2026. The company is focused on developing and commercializing Ultra-Low Temperature Ablation (ULTA) technology for cardiac arrhythmias, specifically ventricular tachycardia (VT). ADGM completed enrollment in its FULCRUM-VT Pivotal FDA Investigational Device Exemption (IDE) study in October 2025 for its vCLAS™ Cryoablation System, which received Breakthrough Device Designation in April 2025. Preliminary acute safety and efficacy results from the FULCRUM-VT trial showed a 97.4% acute clinical success rate and a 2.4% major adverse event rate, including four (1.9%) peri-procedural deaths, with one (0.5%) definitely related to the investigational device. The company plans to share six-month results in April 2026 and submit for FDA approval in the first half of 2026. ADGM also has European CE Mark approval for its vCLAS™ Cryoablation System and is developing a next-generation ULTA catheter and Pulsed Field Cryoablation (PFCA) technology. The global electrophysiology (EP) device market was approximately $14 billion in 2025, with a projected CAGR of 13% to over $33 billion by 2033.

Why It Matters

Adagio Medical's progress with its vCLAS™ Cryoablation System for ventricular tachycardia (VT) could significantly impact the underserved VT patient population, potentially offering a more effective treatment than current radiofrequency (RF) ablation methods. For investors, the successful FDA approval and commercialization of this Breakthrough Device could unlock substantial market growth within the $14 billion global electrophysiology device market, which is projected to reach over $33 billion by 2033. However, the reported 2.4% major adverse event rate, including device-related deaths in the FULCRUM-VT trial, introduces a critical competitive and regulatory hurdle that could affect market adoption and investor confidence, especially against established players and emerging pulsed field ablation (PFA) technologies.

Risk Assessment

Risk Level: high — The company explicitly states, "We have incurred net losses and our financial conditions raise substantial doubt about our ability to continue as a going concern." Furthermore, the FULCRUM-VT trial reported a 2.4% major adverse event rate, including four (1.9%) peri-procedural deaths, with one (0.5%) adjudicated as definitely related to the investigational device, which presents significant regulatory and commercialization risks.

Analyst Insight

Investors should exercise extreme caution and await the full six-month FULCRUM-VT trial results in April 2026 and the subsequent FDA approval decision. Given the going concern warning and device-related deaths, a 'wait and see' approach is prudent before considering any investment, as further negative data or regulatory setbacks could severely impact the stock.

Key Numbers

• $7.0M — Market value of common stock held by non-affiliates (As of June 30, 2025, indicating a small market capitalization.)
• 22,210,459 — Shares of common stock outstanding (As of March 23, 2026, representing the total shares available.)
• October 2025 — Completion of FULCRUM-VT Pivotal FDA IDE study enrollment (Key milestone for regulatory approval pathway.)
• April 2025 — Breakthrough Device Designation by the FDA (Accelerates review process for vCLAS™ Cryoablation System.)
• 97.4% — Acute clinical success rate in FULCRUM-VT trial (High efficacy in eliminating target ventricular arrhythmias.)
• 2.4% — Major adverse event rate in FULCRUM-VT trial (Safety concern, including device-related deaths.)
• 0.5% — Peri-procedural deaths definitely related to investigational device (Significant safety issue for FDA approval.)
• $14B — Global market for electrophysiology (EP) devices (Total market size in 2025, indicating significant opportunity.)
• 13% — Projected compound annual growth rate (CAGR) for EP market (Expected growth to over $33 billion by 2033.)

Key Players & Entities

• Adagio Medical Holdings, Inc. (company) — Registrant
• FDA (regulator) — Investigational Device Exemption (IDE) study approval
• vCLAS TM Cryoablation System (company) — Product under clinical trial
• Nasdaq Stock Market LLC (company) — Exchange for common stock
• Perceptive PIPE Investor (company) — Potential control over key decision making
• Heart Rhythm Society 2026 Conference (company) — Venue for FULCRUM-VT trial results
• U.S. Securities and Exchange Commission (regulator) — Filing oversight
• Delaware (regulator) — State of incorporation

FAQ

Risk Factors

• FDA Approval Uncertainty [high — regulatory]: The company's ability to obtain FDA approval for its vCLAS™ Cryoablation System is contingent on demonstrating favorable safety and efficacy in the FULCRUM-VT Pivotal FDA IDE study. Preliminary results show a high acute success rate (97.4%) but also include a 2.4% major adverse event rate, with 0.5% of peri-procedural deaths definitively related to the investigational device. Further data, including six-month results expected in April 2026, will be critical for the planned submission in the first half of 2026.
• Market Adoption and Competition [medium — market]: While the global electrophysiology (EP) device market is substantial ($14 billion in 2025) and growing (13% CAGR), ADGM faces competition from established players and emerging technologies like Pulsed Field Ablation (PFA). The company's success depends on convincing physicians that its Ultra-Low Temperature Ablation (ULTA) technology offers superior outcomes for Ventricular Tachycardia (VT) compared to current Radio Frequency (RF) and PFA systems, which may be perceived as more established or versatile.
• Clinical Trial Execution and Data Interpretation [medium — operational]: The company's regulatory pathway and market entry are heavily reliant on the successful completion and positive interpretation of its clinical trials, such as the FULCRUM-VT study. Any delays, unexpected adverse events, or data that does not meet regulatory expectations could significantly impact the timeline for FDA approval and commercialization.
• Limited Market Capitalization and Funding Needs [medium — financial]: With a market value of common stock held by non-affiliates at $7.0 million as of June 30, 2025, ADGM has a small market capitalization. This suggests potential challenges in raising substantial capital for further development, commercialization, and scaling operations, which may require significant ongoing investment.
• European CE Mark and Market Access [low — regulatory]: While the company has European CE Mark approval for its vCLAS™ Cryoablation System, this does not guarantee successful market penetration or adoption in Europe. Navigating diverse European healthcare systems, reimbursement landscapes, and local competition will be crucial for realizing revenue from this market.
• Technological Development and Next-Generation Products [medium — operational]: ADGM is investing in developing next-generation ULTA catheters and Pulsed Field Cryoablation (PFCA) technology. The success of these future products, which are not yet commercialized, carries inherent development risks, including technical challenges, regulatory hurdles, and market acceptance.

Industry Context

The global electrophysiology (EP) device market is a significant and rapidly growing sector, valued at approximately $14 billion in 2025 and projected to exceed $33 billion by 2033, with a compound annual growth rate (CAGR) of 13%. This growth is driven by an increasing prevalence of cardiac arrhythmias and advancements in ablation technologies. Adagio Medical's focus on Ventricular Tachycardia (VT) addresses a specific, underserved segment within this broader market, where current treatment options may have limitations.

Regulatory Implications

Adagio Medical's primary regulatory hurdle is obtaining FDA approval for its vCLAS™ Cryoablation System. The company's success hinges on demonstrating a favorable risk-benefit profile in its FULCRUM-VT study, particularly concerning the 0.5% rate of device-related deaths observed in preliminary data. Meeting FDA requirements for safety and efficacy is paramount for market entry and commercialization in the United States.

What Investors Should Do

1. Monitor six-month FULCRUM-VT trial results (expected April 2026).
2. Track FDA submission and approval timeline.
3. Assess competitive landscape and market penetration strategies.
4. Evaluate the company's ability to secure future funding.

Key Dates

• 2025-04-01: FDA Breakthrough Device Designation for vCLAS™ Cryoablation System — Accelerates the regulatory review process, potentially leading to faster market entry if clinical trial results are positive.
• 2025-10-01: Completion of FULCRUM-VT Pivotal FDA IDE study enrollment — Marks a critical milestone in the clinical validation of the vCLAS™ system for treating ventricular tachycardia, paving the way for regulatory submission.
• 2026-04-01: Expected announcement of six-month results from FULCRUM-VT trial — Provides crucial long-term efficacy and safety data, which will be a key determinant for FDA approval.
• 2026-06-30: Planned submission for FDA approval — Represents the culmination of clinical development efforts and the formal request for market authorization in the U.S.

Glossary

Ultra-Low Temperature Ablation (ULTA)

A novel catheter-based technology developed by Adagio Medical for treating cardiac arrhythmias by creating large, durable lesions at very low temperatures. (This is the core proprietary technology of Adagio Medical, differentiating its products in the electrophysiology market.)

Ventricular Tachycardia (VT)

A rapid, abnormal heart rhythm originating in the lower chambers (ventricles) of the heart, which can lead to impaired blood flow and sudden cardiac death. (This is the primary target indication for Adagio Medical's ULTA technology, representing a significant unmet clinical need.)

Investigational Device Exemption (IDE)

A pathway granted by the FDA that allows investigational medical devices to be used in clinical studies for the purpose of gathering safety and effectiveness data. (The FULCRUM-VT study is conducted under an IDE, which is a prerequisite for seeking FDA approval for new medical devices.)

Breakthrough Device Designation

A designation by the FDA that expedites the development, review, and potential approval of medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. (This designation for the vCLAS™ system indicates potential for accelerated FDA review, a positive signal for investors.)

Endocardial

Pertaining to or originating from within the heart's chambers, specifically the inner lining. (Describes the approach of Adagio's catheters, which operate from inside the heart's ventricles.)

Radio Frequency (RF) ablation

A common medical procedure that uses heat generated by electrical current to destroy abnormal tissue, often used in cardiac ablation. (Represents the current standard of care for some cardiac arrhythmias, against which Adagio's ULTA technology is being compared.)

Pulsed Field Ablation (PFA)

A newer ablation technology that uses electrical pulses to destroy tissue, often with a focus on sparing surrounding structures. (An emerging competitor technology in the electrophysiology market that Adagio's ULTA technology will compete against.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text excerpt. The filing focuses on the current business operations, clinical trial progress, and market outlook for Adagio Medical Holdings, Inc.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ADGM The Nasdaq Stock Ma
• $7.0 million — registrant held by non-affiliates was: $7.0 million. As of March 23, 2026, there were 22,
• $14 b — "EP") devices in 2025 was approximately $14 billion, which includes significant recen
• $33 billion — ate of approximately 13%, reaching over $33 billion by 2033. We believe that these market t
• $5.8 b — ssable global market for VT ablation is $5.8 billion, which is comprised of approximat
• $1.6 b — ssable market for VT is estimated to be $1.6 billion, comprised of 200,000 patients. I

Filing Documents

• adgm-20251231x10k.htm (10-K) — 3428KB
• adgm-20251231xex31d1.htm (EX-31.1) — 13KB
• adgm-20251231xex31d2.htm (EX-31.2) — 13KB
• adgm-20251231xex32d1.htm (EX-32.1) — 7KB
• adgm-20251231xex32d2.htm (EX-32.2) — 7KB
• 0002006986-26-000003.txt ( ) — 15273KB
• adgm-20251231.xsd (EX-101.SCH) — 117KB
• adgm-20251231_cal.xml (EX-101.CAL) — 106KB
• adgm-20251231_def.xml (EX-101.DEF) — 520KB
• adgm-20251231_lab.xml (EX-101.LAB) — 838KB
• adgm-20251231_pre.xml (EX-101.PRE) — 831KB
• adgm-20251231x10k_htm.xml (XML) — 2679KB

Business

Item 1. Business 7

Risk Factors

Item 1A. Risk Factors 24

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 79

Cybersecurity

Item 1C. Cybersecurity 79

Properties

Item 2. Properties 80

Legal Proceedings

Item 3. Legal Proceedings 80

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 80 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 81

Reserved

Item 6. Reserved 81

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 82

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 104

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 104

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 164

Controls and Procedures

Item 9A. Controls and Procedures 164

Other Information

Item 9B. Other Information 165

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 165 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 165

Executive Compensation

Item 11. Executive Compensation 165

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 165

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 165

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 165 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 166

Form 10-K Summary

Item 16. Form 10-K Summary 167

Signatures

Signatures 168 Table of Contents This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will" or "would" or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: the timing, progress and results of our clinical trials of our product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to continue to develop innovative, proprietary products that address significant clinical needs in a manner that is safe and effective for patients and easy-to-use for physicians our ability to obtain and maintain regulatory clearances or approvals our ability to demonstrate safety and effectiveness in our sponsored and third-party clinical trials our ability to increase physician awareness our ability to obtain and maintain coverage and adequate reimbursement for procedures using our products our ability to attract and retain skilled research, development, sales and clinical personnel our ability to cost-effectively manufacture, market and sell our products our estimat

Business

Item 1. Business Overview We are a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with our novel, proprietary, catheter-based Ultra-Low Temperature Ablation ("ULTA") technology, formerly known as Ultra-Low Temperature Cryoablation ("ULTC") technology. Our initial focus is on the treatment of ventricular tachycardia ("VT"). VT is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, VT can be fatal. In the United States, VT-associated sudden cardiac death ("SCD") accounts for approximately 300,000 deaths each year. Radio Frequency ("RF") ablation catheters currently used to treat VT were primarily designed and approved for the treatment of atrial fibrillation ("AF") and are therefore not designed to optimally treat the specifics of the ventricular anatomy and disease. As a result, VT procedures performed with current devices can be overly complex, with sub-optimal outcomes, a factor that has potentially led to limited growth in the market for VT ablations. Our clinically tested, proprietary ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Our ULTA approach is built on the hypothesis that large and durable lesions extending through the depth of both diseased and healthy muscular tissue of the ventricle of the heart (ventricular myocardium) is a foundation for improving the effectiveness of VT ablations and patient outcomes. Our differentiated catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial – or inside the heart - approach with no required irrigation. In October 2025, we announced completion of enrollment in our FULCRUM-VT Pivotal FDA Investigational Device Exemption ("IDE") study e

View Full Filing

View this 10-K filing on SEC EDGAR